April 22, 2021
1 min read

Enrollment begins for phase 2 trial of Betaliq glaucoma drop

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Betaliq has enrolled the first patient in a phase 2 trial investigating BTQ-1901 and BTQ-1902 for the treatment of glaucoma or ocular hypertension, according to a press release.

The multicenter, double-masked, parallel-group, dose-ranging study will take place over 12 weeks and aims to enroll about 240 patients. The trial will investigate the safety and efficacy of BTQ-1901 (0.5% and 1% concentrations) and BTQ-1902 ophthalmic suspensions compared with timolol ophthalmic solution 0.5% in adults with elevated IOP due to primary open-angle glaucoma or ocular hypertension. IOP will be compared after 2, 6 and 12 weeks of treatment.

Source: Adobe Stock

“We are very excited to advance our products into the clinic. BTQ-1901 and BTQ-1902 are based on Novaliq’s EyeSol technology that offers important advantages over traditional eye drop technology, including a drop size approximately 25% of the size of water-based drops,” Barry Butler, president and CEO of Betaliq, said in the release.